Skip to main content

Table 2 Characteristics of the included studies across different regions

From: Testing whether the progression of Alzheimer’s disease changes with the year of publication, additional design, and geographical area: a modeling analysis of literature aggregate data

 InternationalNorth AmericaEurope/OceaniaEast AsiaMiddle AsiaSouth America
Number of trials565615553
Total sample size10,842685579945798159
Sample size per arm*135 (19, 639)102 (11, 746)40 (14, 153)37 (19, 268)20 (15, 25)18 (12, 129)
Age, years*73.2 (68.3, 78.3)75.0 (58.0, 81.7)72.1 (64.6, 79.8)74.5 (69.0, 75.4)73.1 (67.7, 73.7)72.6 (71.7, 74.5)
Gender, male (%)*40.3 (30, 59)45.0 (0, 98)38.0 (24.0, 53.3)31.8 (23.8, 37.0)52.1 (45, 60)38.9 (27.1, 41.7)
APOE ε4 carrier, %*58.0 (0, 72)60.0 (41.3, 100)51.1 (44.0, 58.8)54.1**N.A.N.A.
ADAS-cog 11, points*24.7 (18.9, 35.8)23.4 (13.1, 32.2)24.5 (15.4, 34.3)26.9 (23.9, 33.5)25.6 (17.1, 39.3)36.7 (29.3, 39.0)
NPI score, points*10.3 (6.2, 21.8)8.65 (5.0, 16.1)9.2 (7.1, 11.2)9.1 (8.8, 9.3)N.A.N.A.
MMSE score, points*19.4 (15.5, 22.9)20.3 (17.0, 25.4)19.3 (16.8, 23.6)16.1 (14.6, 16.6)13.2**17.4 (17.2, 17.6)
  1. N.A no available information was reported
  2. *Reported mean data were express as median (minimum–maximum)
  3. **Only one study reported the relevant information